Video Highlights
1:43 Ann Melvin, MD, MPH
3:03 Jessica Islam, PhD, MPH
5:36 Parastu Kasaie, PhD
6:48 Patricia de los Rios
|Videos|April 28, 2021
What is the Impact of PrEP and ART on HIV Prevention?
Author(s)John Parkinson
This is our inaugural segment for our new video series, 1 Big Question, where we ask the medical community a question about a significant infectious disease topic and get feedback from them.
Advertisement
Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.
In this episode, our 1 Big Question is: With the greater adaption of pre-exposure prophylaxis (PrEP) therapy and the significant impact antiretroviral therapy (ART) has had, do you think medicine is doing a better job at HIV care and prevention?
We interviewed Ann Melvin, MD, MPH, director of HIV Program, Seattle Children’s Hospital; Jessica Islam, PhD, MPH, epidemiologist, Moffitt Cancer Center; Parastu Kasaie, PhD, assistant scientist, Johns Hopkins Bloomberg School of Public Health; and Patricia de los Rios, Global Medical Affairs director, ViiV Healthcare.
Check out the video to hear their insights.
Advertisement
Related to this article
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.